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bronchodilator FEV1% pred, number of hospital admissions and
ER visits in the year prior to baseline, number of concomitant
diagnoses and BMI were independently associated with EQ-5D
utility. Danish, Spanish and Dutch patients had signiﬁcantly
higher utilities than US patients. French patients had lower util-
ities. Utilities calculated with the US value set were on average
5% higher than utilities calculated with the UK set. CONCLU-
SIONS: Increasing severity of COPD was associated with signif-
icant decline of EQ-5D VAS scores and utilities. These results
demonstrate that a generic instrument can assess COPD impact
on quality of life and that the scores discriminate between
patients groups of known severity. These utilities will be useful
in cost-effectiveness assessments.
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OBJECTIVE: To develop and validate a self-reported question-
naire measuring the severity of dyspnoea and its impact on daily
life. METHODS: A list of daily life activities was selected by the
Scientiﬁc Committee (SC) after an extensive literature review.
This selection was tested during ﬁve interviews with respiratory
physicians, resulting in a modiﬁed list and a preliminary grading
system assessing how dyspnoea impacts on activities. After in-
depth interviews conducted with ten mild-to-severe COPD
patients, a test questionnaire was developed. Six new patients
completed the test questionnaire and commented its contents and
format. Two response choice formats (multiple or exclusive
response) were tested to describe the impact of dyspnoea on
activities. In addition, four new clinicians completed a standard
form evaluating the questionnaire after having used it in clinical
practice with four of their patients. The questionnaire was
revised according to all comments received. RESULTS: Five con-
cepts (self-care, physiological activities, activities at home, activ-
ities outside, and sport) and 48 activities were ﬁrst identiﬁed.
After clinician and patient interviews, some activities were
grouped, split, suppressed or added. The test questionnaire had
20 items. The recall period was set to a week. The descriptive
criteria of the impact of dyspnoea on activities were: abandoned,
slowed, need for pause, need for help, activities modiﬁed,
avoided. After the cognitive debrieﬁng and comments from both
patients and clinicians, the ﬁnal format was established as a mix
of the two tested formats. CONCLUSION: This pilot question-
naire assessing the impact of dyspnoea on COPD patients activ-
ities in real life was well accepted by both patients and doctors.
Further validation is needed to support its use and guide inter-
pretation in clinical practice and clinical trials.
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BACKGROUND: Cough and sputum are leading symptoms of
chronic (obstructive) bronchitis. It is acknowledged that these
symptoms impact patients’ lives, yet they have never been mea-
sured adequately. OBJECTIVE: To develop a self-administered
instrument in ﬁve countries (seven languages) that captures con-
cepts relevant to chronic (obstructive) bronchitis patients who
suffer from cough and sputum. METHODS: After literature
review and appraisal of existing instruments, a conceptual model
was developed and then reviewed by clinical respiratory experts.
Thirty extensive face-to-face concept elicitation interviews were
conducted with patients in ﬁve countries (France, Germany,
Japan, Spain, US). After transcription and domain-mapping of
the interviews in each country, an international item generation
meeting was conducted and a draft questionnaire was simulta-
neously created in ﬁve languages. After clinical expert review,
testing for face and content validity was performed in cognitive
debrieﬁngs in seven languages in six countries with 35 patients
(English for US/UK, French, German, Japanese, and Spanish for
US/Spain). RESULTS: The conceptual model addressed symp-
toms of cough and sputum and their respective impact. The
resulting questionnaire, Cough and Sputum Assessment Ques-
tionnaire (CASA-Q), has 25 items with 6 items for symptoms (3
cough, 3 sputum) and 19 items for the impact of these symp-
toms (12 cough, 7 sputum). The response choices per item
consist of ﬁve options from “never” to “always” or “not at all”
to “extremely”, depending on the context of the item. Due to its
simultaneous item generation in ﬁve languages and ﬁeld testing
in seven languages, item wording overall is following a simple
sentence structure. The ease of understanding and relevance of
each question was found acceptable across languages. CON-
CLUSION: The CASA-Q is a well-developed, patient-based
questionnaire relevant to the assessment of chronic bronchitis.
The CASA-Q, after completion of psychometric validation, may
contribute to a comprehensive patient-centered assessment.
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OBJECTIVES: Analize the patient satisfaction with COPD treat-
ment, and relation with different drugs. METHODS: Cross-
sectional study of 377 patients with COPD controlled in three
primary care settings. Non-random sample: patients were cited
in the health centers and were asked to answer 10 questions
about satisfaction with their treatment (positive scale 1–7). In
this interview the investigators carried out a spirometry. Other
variables measured were: age, sex, comorbidity, and prescribed
treatment. RESULTS: 331 (87.8%) males, age (mean + std) 67.7
+ 8.6 years, 53% had at least another comorbid condition; FEV
1 58% + 21%. In 63 patients (15%) we couldn’t ﬁnd any pre-
scribed treatment. 65% remaining received treatment with:
ß2agonist (55%), anticholinergic (30.8%), inhaled corticos-
teroids (35.5%), oral xantins (19.9%), oral corticosteroids
(7.3%) mucolitics (21.7%) oxygen therapy (4.1%). Only 6.2%
referred an adverse event with treatment. Patient satisfaction
with treatment: 62% satisﬁed because low adverse events; 61%
satisﬁed with drugs; 59.9% satisﬁed about daily life; 58.2%
showed satisfaction with effects onset; 61.4% satisﬁed with sleep
proﬁle; 59.1% showed satisfaction with symptoms control;
60.2% satisﬁed with time of doses. 44% preferred to take med-
ications once a day, 39.8% thought it’s important number of
time they had to take the drugs; 49.6% considered that the times
to take medication in a day doesn’t make it more complicated.
Males feel better symptoms control than females. Satisfaction
was higher in ß2 agonist (less adverse events, less importance on
times of dosage), anticholinergic drug (less adverse events, less
importance on times of dosage) and inhaled corticosteroids (less
